학술논문
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial
Document Type
Article
Author
Thornton, C.A.; Moxley, R.T.; Eichinger, K.; Tanner, M.K.; Heatwole, C.; Mignon, L.; Norris, D.A.; Xia, S.; Bishop, K.M.; Bennett, C.F.; Arnold, W.D.; King, W.; Kissel, J.T.; Ashizawa, T.; Greene, E.P.; Schell, W.; Day, J.W.; Duong, T.; Dent, G.; Herbelin, L.; Statland, J.M.; Johnson, N.E.; Pucillo, E.M.; Leung, D.G.; Stinson, N.; Lott, D.J.; Subramony, S.H.
Source
In: The Lancet Neurology . (The Lancet Neurology, March 2023, 22(3):218-228)
Subject
Language
English
ISSN
14744465
14744422
14744422